Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

- PMLiVE

Pfizer says Xalkori tops chemo as first line therapy

Superior progression free survival for lung cancer patients

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

- PMLiVE

GSK’s cancer vaccine flunks another trial

MAGE-A3 fails to improve survival in lung cancer patients

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

- PMLiVE

Alderley Park ‘will remain flagship bioscience location’

Manchester Science Parks takes over former AstraZeneca site

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

AstraZeneca loses comms head

Neil McCrae to join UK’s Royal Mail

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

- PMLiVE

AZ gets green light for Bydureon pen in US

FDA approval comes after year-long delay

Roche - Basel

Roche drug fails in lung cancer trial

Damages prospects for onartuzumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links